Search

everythinglearnresearchcommunity

for

Search:↓

Early treatment with certain drug combinations improved COVID-19 outcomes and prevented severe disease in males, including those at higher risk.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

The FDA rejected a testosterone drug again due to safety concerns.

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Azathioprine is a safe and effective long-term treatment for severe alopecia areata, significantly improving hair regrowth.

Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.

The FDA approved a new Pfizer drug for hair loss in teens.

Men with male pattern baldness had worse COVID-19 symptoms, but early treatment with certain drugs improved outcomes for all.

Provenge extends prostate cancer survival by about 4 months.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

A reliable method was developed to measure aristolochic acid-I in rat blood.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.